Federal Circuit Reverses Injunction for Avadel CNS Pharmaceuticals

A bipartisan group of lawmakers is advancing the Patent Eligibility Restoration Act, aiming to clarify which inventions are eligible for patent protection and to provide greater certainty for inventors in medical diagnostics, biotechnology, personalized medicine, and artificial intelligence. Supporters, including major medical and biotech organizations, argue the bill is needed because recent court decisions have made patent eligibility unclear, undermining innovation. However, the tech industry opposes the legislation, arguing it could encourage the issuance of weak patents that might be used against companies in litigation. Meanwhile, the Federal Circuit partially reversed and vacated an injunction against Avadel CNS Pharmaceuticals, modifying restrictions related to its FDA approval process for Lumryz in a patent dispute with Jazz Pharmaceuticals. Additionally, a Texas court denied a motion to pause Feit Electric’s patent infringement case against Elong International USA and Xiamen Longstar Lighting, citing the stage of litigation as a factor against granting a stay. These developments highlight ongoing tensions and reforms in U.S. patent law, particularly in the pharmaceutical and technology sectors.